AngioDynamics Reports Fiscal 2016 First Quarter Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/31/2026
Go back to AngioDynamics Reports Fiscal 2016 First Quarter Results
October 9, 2015 8:55 AM EDT
Canaccord Genuity maintained a Buy rating on AngioDynamics (NASDAQ: ANGO), and cut the price target to $17.50 (from $19.00), following the company's 1Q16 earnings results. ANGOs salesforce has now converted approximately 45% of Morpheus customers over to BioFlow, with BioFlow PICC sales up 22% during the quarter.... More
October 9, 2015 8:12 AM EDT
Piper Jaffray maintained a Neutral rating on AngioDynamics (NASDAQ: ANGO), and cut the price target to $14.00 (from $18.00), following the company's 1Q16 earnings results. Revenues missed, coming in at $83.7M, and earnings were in line with expectations.
Analyst Thomas Gunderson commented, "ANGO essentially... More
October 8, 2015 4:04 PM EDT
AngioDynamics (NASDAQ: ANGO) reported Q1 EPS of $0.11, in-line with the analyst estimate of $0.11. Revenue for the quarter came in at $83.7 million versus the consensus estimate of $84.7 million.
AngioDynamics sees Q2 2016 EPS of $0.13-$0.15, versus the consensus of $0.16. AngioDynamics sees Q2 2016 revenue of $87-91 million,... More
